Ananda Pharma PLC has announced plans to withdraw its shares from the AQSE Growth Market and re-register as a private company, proposing to continue operations under the name Ananda Pharma
Ananda Pharma to delist from AQSE and go private to refocus on drug development
Ananda Pharma PLC has announced plans to withdraw from the AQSE Growth Market and re-register as a private company, citing the high cost of being publicly listed, regulatory complexity and
Ananda Pharma plc (AQSE: ANA, OTC: ANANF) Webinar Presentation Release
Ananda Pharma plc (AQSE: ANA, OTC: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, is pleased to announce that the post annual report corporate
Ananda Pharma plc (AQSE: ANA) Appointment of Commercial Adviser
Ananda Pharma plc (AQSE: ANA), a UK company focused on the development of cannabinoid therapies targeting the treatment of complex, chronic inflammatory pain conditions is pleased to announce the appointment of Andy Rust as
An Introduction to Ananda Developments
Finance Director Jeremy Sturgess-Smith introduces Ananda Developments, outlining the company’s mission, strategic focus, and what makes it distinct within the CBD and drug development sectors.